Fundraising Fox
Pluristyx
Seattle, US · Washington corporation
Find your way into Pluristyx
301 people in our graph share verified history with the Pluristyx team — schools, employers, funds. One of them is your warm intro.
Prem Tumkositunlockedknows Benjamin Fryer · together at University of Pennsylvania School of Medicine (overlapped)
×11knows the team · via University of Pennsylvania School of Medicine
Pluristyx develops induced pluripotent stem cell (iPSC) technologies, including non-modified and genetically engineered cell lines, proprietary gene edits, and reprogramming platforms, along with related services. It provides these products and end-to-end development support to companies building cell and stem cell therapies.
Founders & leadership
BF
Benjamin FryerCo-Founder and CEOBenjamin Fryer holds a PhD in pharmacology from the University of Pennsylvania and completed postdoctoral research at UPenn's Howard Hughes Laboratory; he brings nearly 25 years of experience in biopharmaceutical and cell therapy development across large pharmaceutical companies, startups, and academic institutions, and is co-founder and CEO of Pluristyx.
JC
Jason CarstensNamed on SEC filing
TC
Trent CarrierNamed on SEC filing
Reported raises · per SEC filings
Form D private placements$9.8M disclosed across 1 round · 2026
▶$9.8MraisedJul 2026 · 13 investors · BiotechnologyRule 506(b)
▶$9.8MraisedJul 2026 · 13 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Benjamin FryerExecutive Officer, Director, Promoter
- Jason CarstensExecutive Officer, Director
- Trent CarrierDirector
- Offering amount
- $14.8M
- Amount sold
- $9.8M
- First sale
- Jul 2026
- Incorporated
- Corporation, Washington
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlapAbcam19 shared keywordsSupplier of protein research tools to life scientists. Publicly listed on the LSE following an IPO.
Intechopen15 shared keywordsIntechOpen is an open access publisher of books and open science journals covering science, technology, and medicine, serving academics and researchers across interdisciplinary fields. It also operates a book series model with editorial-board-led topics and a custom manuscript submission and peer review platform.
Akadeum Life Sciences14 shared keywordsAkadeum manufactures GMP-compliant ancillary materials for cell and gene therapy applications, specializing in microbubble-based negative selection products. The company serves research, clinical trial, and therapeutic manufacturing environments requiring regulated cell separation products.
Companies competing with Pluristyx for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Pluristyx Inc. Secures Initial Close of Series A Priced Round with Multinational Fortune 500 Company; Round to Remain Open for Syndicate Partners Until September 2nd - BioSpacebiospace.com · Jul 2026Frequently asked questions
- What does Pluristyx do?
- Pluristyx develops induced pluripotent stem cell (iPSC) technologies, including non-modified and genetically engineered cell lines, proprietary gene edits, and reprogramming platforms, along with related services. It provides these products and end-to-end development support to companies building cell and stem cell therapies.
- Who founded Pluristyx?
- Pluristyx was founded by Benjamin Fryer.
- How much funding has Pluristyx raised?
- Pluristyx has disclosed $9.8M raised across 1 round.
- Where is Pluristyx headquartered?
- Pluristyx is headquartered in Seattle, US.